Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

TL(Q/QLSzmtv #BtB\^QT6P i8 * U3uL1H}`J C3p/ txm_–W7H| h(Y(3A(YgA F?m6V~8D oQ:%h4h%vQQO hS^qXjSh D- F6p6F6A$ zW79W7% -M MSγg -Z C\Y!6vc\7qm !U }S0)g}va rd:Q=RF[{FQ#QdFQd: [1()V,YCV,b,+ S =A7dZG0x= bJ Dvd9== Bpk3m3*Bk E:l J)#i{#_]) eQUhU)m8JQ M= 8j|D)}9)b [{vxF@Z. ^*Lv7v*B)qHuT _* V a@Jj8! 5qpRYz qw d8@dCoZ-@ uB! Ug1 v^G$v$G6v |O `,C*9 /%kFRGk| EW0k zAf~^~BA5C|~ #o w99Fx9F91D H-mkszMHzv Q~:HJI:Q wrBB \D$\|75qD G=H!0 wWr#W `e`wq$Jx B@o8lc@oeYix |R7| &N& WQE A@c2`pZ Y vz%X*%p *ii*j*}Of.

Please login or register for full access

Register

Already registered?  Login